Fig. 4
Differences in the populations selected by the investigated algorithms. a SP263 (TC/IC ≥25%) versus SP142 (ICTumorArea ≥ 5%), b PD-L1 IHC 22C3 pharmDx (CPS ≥1), c PD-L1 IHC 22C3 pharmDx (CPS ≥10), and d PD-L1 IHC 28–8 pharmDx (TC ≥1%) algorithms, with subject numbers shown in e. CPS combined positive score, IC immune cell, IHC immunohistochemistry, PD-L1 programmed cell death ligand-1, TC tumor cell